S Madsbad, T Krarup, CF Deacon, JJ Holst - Current Opinion in Clinical Nutrition & Metabolic Care, 2008 - journals.lww.com Recent findings: The injectable glucagon-like peptide-1 receptor agonists
exenatide significantly improves glycaemic control, with average reductions in
haemoglobin A1c of about 1.0%, fasting plasma glucose of about 1.4 mmol/l, ... Cited by 24 - Related articles - All 2 versions
E Ferrannini, V Fonseca, B Zinman, D … - Diabetes Obes Metab, 2009 - interscience.wiley.com Duality of interests: EF has received consulting fees from Novartis
Pharmaceuticals. VF has received funding for research and consulting/speaking
for Novartis as well as from other manufacturers of drugs in this class, ... Cited by 7 - Related articles - All 2 versions
B Ahrén - Expert Opin. Emerging Drugs, 2008 - informahealthcare.com Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of
glucagon-like peptide-1 (GLP-1). This increases circulating levels of active
GLP-1, stimulates insulin secretion and inhibits glucagon secretion, ... Cited by 7 - Related articles - All 8 versions
DM Kendall, RM Cuddihy, RM Bergenstal - European Journal of Internal Medicine, 2009 - Elsevier Incretin-based therapies address the progressive nature of type 2 diabetes
mellitus, not only by addressing glucose control but also with weight-neutral
(ie, dipeptidyl peptidase–4 inhibitors sitagliptin and vildagliptin) and ... Cited by 4 - Related articles - All 38 versions
JH Wani, J John-Kalarickal, VA Fonseca - Cardiology Clinics, 2008 - Elsevier Type 2 diabetes mellitus is a metabolic disease leading to microvascular and
macrovascular complications including coronary artery disease and stroke.
Management of diabetes has been challenging, particularly in the presence ... Cited by 4 - Related articles - All 27 versions
E Bosi, F Dotta, Y Jia, M Goodman - Diabetes Obes Metab, 2009 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 3 - Related articles - All 2 versions
A Garber - Diabetes Obesity and Metabolism, 2008 - interscience.wiley.com Type 2 diabetes is a chronic, progressive disease characterized by an inexorable
decline in β-cell function. Current treatments fail to manage this continued
β-cell failure, and eventually patients with type 2 diabetes will require ... Cited by 2 - Related articles - All 2 versions
